Inside Precision Medicine September 19, 2024
NanoVation Therapeutics has inked a $600M plus partnership with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases. The deal brings together NanoVation’s proprietary long-circulating lipid nanoparticle (LNP) technology with Novo’s expertise in cardiometabolic and rare disease R&D. LNPs allow RNA delivery to cells outside of the liver.
“We founded NanoVation to enable partners to overcome the challenges of conventional nucleic acid delivery systems,” said Dominik Witzigmann, PhD, co-founder and CEO of NanoVation Therapeutics. “This agreement with Novo Nordisk and ongoing work with companies in the cell and gene therapy space is validation of the potential of our LNP technologies to enable the next generation of life-changing genetic medicines.”
The companies will collaborate on two lead base-editing...
Today's Sponsors
Today's Sponsor